A Phase 3 trial of aficamten versus placebo in adults with symptomatic non-obstructive hypertrophic cardiomyopathy lists August 31, 2026, as its primary completion date. The ClinicalTrials.gov record lists 500 participants and an active, not recruiting status; it does not provide results.
Background
The study is evaluating aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy, or nHCM. Its registry summary says the trial will assess quality of life, exercise capacity, and clinical outcomes compared with placebo. The supplied record does not describe the drug’s mechanism, prior approvals, or the prevalence of the condition.
Trial design
Identified as NCT06081894, the study is listed as Phase 3 and plans to enroll 500 adults with symptomatic non-obstructive hypertrophic cardiomyopathy. The interventions are aficamten and placebo. The registry lists the study as active, not recruiting, and gives August 31, 2026, as the primary completion date. No primary-outcome entries are included in the supplied record.
What this means
The listing describes a placebo-controlled evaluation of aficamten across quality of life, exercise capacity, and clinical outcomes, but provides no outcome measurements or analyses. The record therefore does not establish whether aficamten improved these measures or how its safety compared with placebo. The listed primary completion date is a trial timeline entry, not a report of completed results.
Source
Source: ClinicalTrials.gov, study registry record for “A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM).” The record lists primary completion for August 31, 2026. Available at clinicaltrials.gov/study/NCT06081894.